Oxford Nanopore Technologies PLC
LSE:ONT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
86.55
208.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Oxford Nanopore Technologies PLC
Oxford Nanopore Technologies PLC
Investor Relations
Oxford Nanopore Technologies PLC stands as a pioneering force in the field of genomics, transforming the landscape of DNA and RNA sequencing. Founded as a spin-off from the University of Oxford, the company gained recognition with its distinctive nanopore sequencing technology, which radically differs from traditional sequencing methods. Traditional sequencing often involves a process that can be expensive, time-consuming, and complex. However, Oxford Nanopore's approach uses tiny, porous apertures coupled with electrical signals to read genetic codes directly. This technology allows for the sequencing of long DNA strands in real-time, providing not only speed and efficiency but also the versatility to handle a wide range of samples, from environmental to clinical applications. By making sequencing more accessible and portable through their critically acclaimed MinION device, the company has managed to capture significant interest and investment from researchers across diverse scientific fields.
The business model of Oxford Nanopore Technologies is built upon a strategic blend of product sales, including their sequencing devices and associated consumables, alongside providing commercial sequencing services. Their revenue streams are anchored by the MinION, GridION, and PromethION devices, each catering to varied throughput needs and scales of operation. Sales of these devices are complemented by a continuous income from consumable sales, essential for each sequencing run, which helps to embed their technology deeply within the workflows of their users. Additionally, the company's expansion into data analysis services further diversifies their income, utilizing their specialized expertise to assist customers in interpreting and utilizing complex genomic data. This multifaceted approach not only solidifies their position in the genomics market but also ensures multiple pathways for generating sustained revenue growth.
Oxford Nanopore Technologies PLC stands as a pioneering force in the field of genomics, transforming the landscape of DNA and RNA sequencing. Founded as a spin-off from the University of Oxford, the company gained recognition with its distinctive nanopore sequencing technology, which radically differs from traditional sequencing methods. Traditional sequencing often involves a process that can be expensive, time-consuming, and complex. However, Oxford Nanopore's approach uses tiny, porous apertures coupled with electrical signals to read genetic codes directly. This technology allows for the sequencing of long DNA strands in real-time, providing not only speed and efficiency but also the versatility to handle a wide range of samples, from environmental to clinical applications. By making sequencing more accessible and portable through their critically acclaimed MinION device, the company has managed to capture significant interest and investment from researchers across diverse scientific fields.
The business model of Oxford Nanopore Technologies is built upon a strategic blend of product sales, including their sequencing devices and associated consumables, alongside providing commercial sequencing services. Their revenue streams are anchored by the MinION, GridION, and PromethION devices, each catering to varied throughput needs and scales of operation. Sales of these devices are complemented by a continuous income from consumable sales, essential for each sequencing run, which helps to embed their technology deeply within the workflows of their users. Additionally, the company's expansion into data analysis services further diversifies their income, utilizing their specialized expertise to assist customers in interpreting and utilizing complex genomic data. This multifaceted approach not only solidifies their position in the genomics market but also ensures multiple pathways for generating sustained revenue growth.
You don't have any saved screeners yet
